Every 8-K that DBV TECHNOLOGIES SA (DBVTF) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow DBVTF and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full DBVTF filings page.
DBV Technologies reported second-quarter and half-year 2026 results, highlighting continued investment in its VIASKIN® Peanut Patch program and commercial readiness. Under U.S. GAAP, operating income was $1.6 million for the first half of 2026, while operating expenses rose to $100.1 million, driven by higher R&D, sales and marketing, and general and administrative costs.
The company recorded a half-year net loss of $98.0 million and basic/diluted net loss per share of $(0.23), compared with $(0.58) a year earlier, reflecting a significantly strengthened equity base. Net cash used in operating and investing activities increased to $102.6 million. Cash and cash equivalents were $174.9 million as of June 30, 2026, and management currently forecasts funding into the third quarter of 2027, assuming continued focus on the VIASKIN® Peanut Patch and related regulatory and commercial activities, including a planned BLA submission in the third quarter of 2026.
DBV Technologies S.A. provided an update on its planned Biologics License Application (BLA) seeking U.S. marketing approval for the VIASKIN® Peanut Patch in children aged four through seven years. After detailed, collaborative discussions with the FDA on data organization and formatting, the agency has not requested additional data. DBV will use the feedback to refine the submission and now anticipates filing the BLA in the third quarter of 2026. The company will discuss the update on a conference call and webcast on June 29 at 5:00 p.m. ET.
DBV Technologies S.A. approved a new 2026 Performance Share Unit Plan and granted its CEO, Daniel Tassé, 4,060,000 Performance Share Units (PSUs). Each PSU is a conditional right to receive one ordinary share.
Vesting depends on FDA approval of biologics license applications for Viaskin Peanut in specified age groups and a continued employment condition through July 1, 2028. PSUs that do not meet performance conditions by this date are forfeited. Vested shares are scheduled for delivery in four installments on July 1, 2028, January 1, 2029, July 1, 2029 and January 1, 2030.
Upon a Change in Control, performance conditions are deemed achieved and only the employment condition remains. The plan includes special rules for death, disability, qualifying retirement, termination without cause or for good reason, Section 409A deferral for specified employees, and allows the Board to substitute equivalent cash if the CEO is not a French tax resident at delivery.
DBV Technologies S.A. reported the results of its Annual Combined Meeting of Shareholders and related changes to its bylaws. Shareholders approved amendments to Articles 18 and 21 to align the Ordinary Share Record Date with French decree nº2026-94 of February 13, 2026. They also amended Article 15 to set a Chief Executive Officer age limit of 70 years, with the CEO’s mandate ending at the shareholders’ meeting approving the financial statements for the year in which that age is reached. Across the ordinary and extraordinary agendas, the thirty-nine proposals received strong support, with many resolutions attracting around 190 million votes in favor versus much smaller opposition, confirming broad shareholder backing for the updated governance framework.
DBV Technologies S.A. adopted a new 2026 Performance Share Unit Plan and granted its CEO, Daniel Tassé, 1,740,000 Performance Share Units (PSUs) effective May 5, 2026. Each PSU is a conditional right to receive one ordinary share.
Half of the PSUs depend on each of two performance conditions tied to U.S. FDA acceptance for review or approval of biologics license applications for Viaskin Peanut, plus a continued employment requirement through July 1, 2028. Unmet PSUs by that date are forfeited. Vested shares are scheduled for delivery in four installments from July 1, 2028 through January 1, 2030, with change-in-control, death, disability, qualifying retirement and certain terminations receiving tailored treatment under the Plan, including potential cash settlement if the CEO is not a French tax resident.
DBV Technologies reported first quarter 2026 results showing higher spending as it prepares for potential commercialization of its VIASKIN Peanut patch. Net loss widened to $47.6 million from $27.1 million a year earlier as research, sales, and administrative expenses increased sharply.
Research and development expenses rose to $33.4 million, while sales and marketing and general and administrative costs climbed to $4.8 million and $10.5 million, respectively. Despite the larger loss, basic and diluted net loss per share improved from $(0.26) to $(0.11) due to a strengthened equity base.
DBV ended March 31, 2026 with $229 million in cash and cash equivalents, up from $194 million at year-end 2025, supported by $89 million of financing cash flows from warrant exercises. Management currently expects this cash to fund operations into the second quarter of 2027.
DBV Technologies reported full-year 2025 results showing continued investment ahead of a potential launch of its VIASKIN® Peanut Patch. Under U.S. GAAP, operating income was $5.6 million for the year ended December 31, 2025, up from $4.2 million in 2024, mainly from higher French research tax credits.
Research and development expenses rose to $116.7 million, while general and administrative expenses increased to $32.8 million, reflecting clinical progress and launch preparation. Net loss widened to $147.0 million versus $113.9 million in 2024, though net loss per share improved to $1.05 from $1.17. Including $94 million of warrant-related proceeds received in January 2026, management expects existing cash and cash equivalents to fund operations into the second quarter of 2027, based on current plans focused on the VIASKIN Peanut Patch.
DBV Technologies filed a report highlighting additional positive data from its successful Phase 3 VITESSE study of the VIASKIN® Peanut Patch in peanut-allergic children aged 4 to 7 years.
The trial met its primary endpoint, with 46.6% of children on VIASKIN Peanut classified as responders at 12 months versus 14.8% on placebo, a 31.8% difference in response rates (95% CI 24.5–39.0%, p<0.001). The company states these data support a planned Biologics License Application submission to the FDA in the first half of the year.
DBV Technologies S.A. reported that Daniel Soland has resigned from its Board of Directors and from the Board’s compensation committee, effective September 18, 2025. The company states that his resignation was not due to any dispute or disagreement with the company or the Board, indicating an orderly departure rather than a conflict-driven exit.
DBV Technologies also issued a press release on September 18, 2025 to announce this Board change, which is included as an exhibit to this report for additional background on the transition.